ASMBR 2018


September 2018- Entera presented "An oral PTH(1-34) formulation with a pharmacokinetic profile optimized for the treatment of osteoporosis" for its Osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Montreal Canada. Osteoporosis is a disease that causes bones to become less dense and more fragile which increases the risk of fractures. Entera presented results from a clinical study comparing the commercial SC injection of PTH(1-34) to Entera’s oral formulation (EB613) designed to have a shorter drug exposure, potentially enhancing its anabolic effect on the bone.

pdf See poster